Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
immunotherapy |
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:alternativeName |
gptkb:Tremelimumab
|
| gptkbp:ATCCode |
L01XC28
|
| gptkbp:CASNumber |
527747-85-1
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:developedBy |
gptkb:Pfizer
gptkb:AstraZeneca |
| gptkbp:drugClass |
immune checkpoint inhibitors
|
| gptkbp:hasMolecularFormula |
C6428H9954N1714O2016S46
|
| gptkbp:hasUNII |
6Z5F2A6V8I
|
| https://www.w3.org/2000/01/rdf-schema#label |
CP-675,206
|
| gptkbp:indication |
gptkb:non-small_cell_lung_cancer
melanoma mesothelioma hepatocellular carcinoma |
| gptkbp:isHumanized |
yes
|
| gptkbp:isIgG2 |
yes
|
| gptkbp:legalStatus |
investigational
|
| gptkbp:mechanismOfAction |
immunotherapy
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:target |
gptkb:CTLA-4
|
| gptkbp:usedIn |
gptkb:cancer
|
| gptkbp:bfsParent |
gptkb:Tremelimumab
|
| gptkbp:bfsLayer |
7
|